Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
By Deena Beasley Aug 4 (Reuters) - Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss due to costs
Merck's (MRK) "HIV pipeline" is brewing in the background, as weekly treatment are interesting and s
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
Merck & Co., Inc. (NYSE:MRK) outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral HIV regimen and its plans for a monthly oral pre-exposure prophylaxis, or PrEP, candidate. Comp
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday after market hours. Here’s what to expect.
The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.
The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.
Gilead Sciences stock has delivered a strong 130.1% return over the past 5 years, which raises a clear question for investors about how much value is already reflected in the current US$132.73 share price. The latest valuation checks paint a mixed picture, with some signals pointing to the shares screening as undervalued while others are more cautious. Over 5 years, Gilead Sciences has returned 130.1%. This puts current buyers in the position of assessing whether that long run of gains still...
Gilead Sciences (GILD) is back in focus after regulators in Europe issued a positive opinion on expanding Trodelvy’s use alongside Keytruda for certain advanced triple negative breast cancer patients. See our latest analysis for Gilead Sciences. Alongside the positive Trodelvy opinion, Gilead Sciences shares have seen a 5.07% 30 day share price return and a 9.15% year to date share price return, while the 5 year total shareholder return of 130.07% reflects strong longer term compounding. If...
GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.
Atea Pharmaceuticals Inc. announced on Tuesday positive topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis C virus infection. The C-BEYOND study enrolled 905 patients and met its primary...
Gilead Sciences (GILD) reached $134.32 at the closing of the latest trading day, reflecting a +2.91% change compared to its last close.
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Atea Pharmaceuticals (AVIR) said Tuesday a pivotal phase 3 trial of its experimental combination the
Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.
Most biotech investors treat FBT and IBB as two names for the same trade, but the structural differences buried in their index methodologies have produced shockingly different outcomes depending on where the market's momentum actually lives.
Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.
GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.
A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.
Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
